Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571832 | 0.92 | HIF1A (0.69) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL7135144 | 0.92 | HIF1A (0.69) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL13692233 | 0.92 | HIF1A (0.69) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL9835911 | 0.89 | HIF1A (0.71) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL13655915 | 0.88 | HIF1A (0.67) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL18278997 | 0.85 | HIF1A (0.80) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL10381829 | 0.85 | HIF1A (0.65) | HIF1APGRSERPINA6LMNAAR | |
| Hydrochloric Acid SCHEMBL9836539 | 0.84 | HIF1A (0.64) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL13692155 | 0.82 | HIF1A (0.79) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL13669674 | 0.82 | HIF1A (0.77) | HIF1APGRSERPINA6LMNAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4646217-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | Stellular Bio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250243228-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240360164-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240246947-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240132528-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4149497-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | Platelet Biogenesis, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4125947-A1 | NOVEL ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES | Platelet Biogenesis, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11572358-B2 | Solid forms of an sGC stimulator | CYCLERION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| WO-2022153308-A1 | TOPICAL COMPOSITION | RICH PSC LTD. (IL) | 2022-07-21 | — | — | WO | disclosed |
| CN-114736240-A | Phosphorus prodrugs of sGC stimulators | 赛克里翁治疗有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | HIF1A 504/4885PGR 3550/4885SERPINA6 2638/4885 |
| US-20250243228-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS | P2RY1, P2RY11, GMPS | HIF1A 2213/4885PGR 149/4885SERPINA6 4376/4885 |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | HIF1A 1314/4885PGR 3228/4885SERPINA6 1359/4885 |
| US-20240246947-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | HIF1A 1314/4885PGR 3228/4885SERPINA6 1359/4885 |
| US-11572358-B2 | Solid forms of an sGC stimulator | GUCY1A2, PRKG1, GUCY1A1 | HIF1A 1241/4885PGR 3213/4885SERPINA6 1337/4885 |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | HIF1A 2213/4885PGR 149/4885SERPINA6 4376/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | HIF1A 426/4885PGR 3507/4885SERPINA6 1965/4885 |
| US-20240132528-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | HIF1A 2213/4885PGR 149/4885SERPINA6 4376/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | HIF1A 1864/4885PGR 157/4885SERPINA6 894/4885 |
| US-20240360164-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | HIF1A 2213/4885PGR 149/4885SERPINA6 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.